Anti-TICAM2 antibody (140-170) {FITC}

Cat# NB-22-60097-100

Size : 100ug

Request more information

Contact local distributor :


Phone : +1 850 650 7790

General Info

Host: Rabbit
Applications: ELISA/WB
Reactivity: Cat/Human/Monkey/Pig
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-TICAM2 (140-170) is suitable for use in ELISA and Western Blot research applications.
Clonality: Polyclonal
Conjugation: FITC
Isotype: IgG
Purification: Affinity Purified
Concentration: 0.60-0.65 µg/µl
Dilution Range: WB: 1:250
DB: 1:10, 000
ELISA: 1:10, 000
IP: 1:200
Storage Instruction: Store at-20°C for long term storage. Avoid freeze-thaw cycles.

Information

Gene Symbol: TICAM2
Gene ID: 100302736/353376
Uniprot ID: TCAM2_HUMAN
Immunogen Region: 140-170
Immunogen: Synthetic peptide taken within amino acid region 140-170 on human TIRAP3b long form protein.

Description

Tissue Specificity Expressed in spleen, prostate, testis, uterus, small intestine, colon, peripheral blood leukocytes, heart, placenta, lung, liver, skeletal muscle, and pancreas Isoform 2 is ubiquitously expressed (at lower levels than isoform 1).
Post Translational Modifications Phosphorylated by PRKCE in response to LPS. Phosphorylation is essential for its function. It is depleted from the membrane upon phosphorylation. Tyrosine phosphorylation is inhibited by phosphatase PTPN4. Isoform 1 is myristoylated. Required for membrane association which is critical for its ability to initiate efficient signaling.
Function Functions as sorting adapter in different signaling pathways to facilitate downstream signaling leading to type I interferon induction. In TLR4 signaling, physically bridges TLR4 and TICAM1 and functionally transmits signal to TICAM1 in early endosomes after endocytosis of TLR4. In TLR2 signaling, physically bridges TLR2 and MYD88 and is required for the TLR2-dependent movement of MYD88 to endosomes following ligand engagement. Involved in IL-18 signaling and is proposed to function as a sorting adapter for MYD88 in IL-18 signaling during adaptive immune response. Forms a complex with RAB11FIP2 that is recruited to the phagosomes to promote the activation of the actin-regulatory GTPases RAC1 and CDC42 and subsequent phagocytosis of Gram-negative bacteria. Isoform 2: Proposed to inhibit LPS-TLR4 signaling at the late endosome by interaction with isoform 1 thereby disrupting the association of isoform 1 with TICAM1. May be involved in TLR4 degradation in late endosomes.
Protein Name Tir Domain-Containing Adapter Molecule 2
Ticam-2
Putative Nf-Kappa-B-Activating Protein 502
Trif-Related Adapter Molecule
Toll-Like Receptor Adaptor Protein 3
Toll/Interleukin-1 Receptor Domain-Containing Protein
Myd88-4
Database Links Reactome: R-HSA-140534
Reactome: R-HSA-166016
Reactome: R-HSA-166166
Reactome: R-HSA-2562578
Reactome: R-HSA-6798695
Reactome: R-HSA-936964
Reactome: R-HSA-937041
Reactome: R-HSA-937072
Reactome: R-HSA-975163
Cellular Localisation Isoform 1: Cytoplasm
Golgi Apparatus
Cell Membrane
Endoplasmic Reticulum
Early Endosome Membrane
Late Endosome Membrane
Cell Projection
Phagocytic Cup
Localized To The Plasma Membrane As A Result Of Myristoylation
Phosphorylation On Ser-16 Leads To Its Depletion From The Membrane
Upon Lps Stimulation Colcoalizes With Isoform 2 In Late Endosomes
Isoform 2: Endoplasmic Reticulum
Translocates To Late Endosomes Upon Lps Stimulation Where It Colcoalizes With Isoform 1
Alternative Antibody Names Anti-Tir Domain-Containing Adapter Molecule 2 antibody
Anti-Ticam-2 antibody
Anti-Putative Nf-Kappa-B-Activating Protein 502 antibody
Anti-Trif-Related Adapter Molecule antibody
Anti-Toll-Like Receptor Adaptor Protein 3 antibody
Anti-Toll/Interleukin-1 Receptor Domain-Containing Protein antibody
Anti-Myd88-4 antibody
Anti-TICAM2 antibody
Anti-TIRAP3 antibody
Anti-TIRP antibody
Anti-TRAM antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance